Close Menu

Precision Oncology News: Breaking News

The Quantum Leap-sponsored I-SPY 2 trial will evaluate Byondis' antibody-drug conjugate SYD985 against standard of care for HER2-low, early-stage breast cancer.

Repotrectinib is an investigational drug intended for the treatment of patients with advanced solid tumors harboring ROS1, NTRK1-3, or ALK molecular rearrangements.

Enhertu, or trastuzumab deruxtecan, will also receive accelerated assessment by the European Medicines Agency's Committee for Medicinal Products for Human Use.

In the Phase III ASCENT trial, antibody-drug conjugate Trodelvy was able to improve clinical outcomes in patients with relapsed or refractory metastatic TNBC who received at least two therapies prior.

The Phase Ib/II trial will assess dosage and antitumor activity of MEN1611 plus Erbitux for patients with PIK3CA-mutated, RAS and RAF wildtype advanced colorectal cancer.

The initial investment is led by Debiopharm, which will collaborate with the Israeli startup to accelerate discovery of biomarkers for oncology drug response.

A Myriad Genetics-funded team found that an 86-SNV polygenic score could modify breast cancer risk in women with pathogenic mutations in cancer risk genes.

The Cambridge, Massachusetts-based company recently reported positive interim results for the RET-targeting agent from the Phase I/II ARROW study.

In the Phase II TAPUR trial, palbociclib monotherapy demonstrated "modest antitumor activity" in heavily pretreated non-small cell lung cancer patients with CDKN2A alterations. 

Bolt's lead candidate, BDC-1001, is an immune-stimulating antibody conjugate currently being studied in a Phase I clinical trial in HER2-expressing solid tumors.

After DS-1062 demonstrated encouraging activity in lung cancer, the firm decided to add a cohort of TNBC patients whose tumors express TROP2.

A case series in partnership with My Gene Counsel to highlight the challenges genetics professionals and oncologists are grappling with as genetic testing is increasingly used in patient care.

The approval is supported by a randomized trial showing that pembrolizumab nearly doubled progression-free survival compared to the standard chemotherapy regimen.

Healthcare professionals can inject the regimen, containing Perjeta, Herceptin, and hyaluronidase, in patients' homes after intravenous chemotherapy.

The company will test whether ALRN-6924 can protect patients with TP53-mutated small-cell lung cancer from the off-target effects of chemotherapy topotecan.

The agent has been approved for both treatment-naïve and previously treated patients whose tumors have a mutation that leads to MET exon 14 skipping.

Burning Rock also said it will continue to develop companion diagnostics-related products based on next-generation sequencing technology.

The new drug developer's current pipeline consists of CAR-NK cell drugs targeting HER2-positive tumors and CD19-positive B-cell malignancies, as well as a universal NK cell therapy.

Developers are improving and expanding the software that has been helping match patients to molecularly targeted drugs at the institute for over three years.

Initial data on the PARIS test, combining functional drug testing and DNA sequencing, showed concordance between its predictions and patients' treatment responses.

The committee recommended the tumor-agnostic drug for use in the Cancer Drugs Fund while awaiting mature survival data from ongoing clinical trials.

In a Phase Ia/Ib study, the anti-TIGIT antibody and Tecentriq combination had better anti-tumor activity than tiragolumab alone, particularly in PD-L1 expressing lung cancers.

Researchers reported a correlation between ctDNA clearance and progression-free survival in EGFR-positive, MET-amplified patients treated with Tagrisso and savolitinib.

Comprehensive analysis by a team led by Elaine Mardis has given 93 percent of around 150 pediatric cancer patients at least one medically actionable finding.

In the study, pelareorep will be combined with paclitaxel and the PD-L1 inhibitor Bavencio in patients with HR-positive, HER2-negative breast cancer.

Pages